The #1 Peptide Mistake According to a Doctor on the FDA's Peptide Panel| Gabriel Alizaidy, MD

Implement my protocols → https://ddtmtd.co/apply

Nationwide Bloodwork, no doctor visit → https://ddtmtd.co/Amplify

Reliable third-party tested research compounds: Janus Optimize Code DDTSkool

Join my Enhancement Education Community → https://ddtmtd.co/skool

You're collecting peptides like Pokémon. That's Dr. Gabriel Alizaidy's diagnosis in the first ninety seconds of this episode of the DDT Method Podcast, and the next hour is the cure: pick the right tool for the right job, run one or two things at a time, dose low and slow, and let someone who isn't you make the call. Drew's intake forms went from three entries to forty-seven. Both of them have been guilty. Nobody gets to feel superior here.

The section people will replay is mitochondria. SS-31 is physical therapy for your mitochondria. MOTS-c is exercise. Run them in the wrong order and you get the pattern Gabe sees constantly: two great injections, then tired all the time. He explains mitochondria the way he'd explain them to his mom (miles per gallon, exhaust, scrap the broken car), why diet, sleep, and training come before anything goes in a syringe, why MOTS-c works better with exercise instead of replacing it, and the MOTS-c doses he won't touch. Then the wide-angle stuff: red light therapy and nitric oxide, oxytocin as the peptide he uses before public speaking, myostatin inhibitors and FLGR from a safe distance, how Drew finds new compounds before they hit Instagram, why phase 3 trials for BPC-157 and TB-500 aren't coming, and the decision-fatigue conversation that lands where wealthy people already live: get an advisor for this part of your life. First peptide or fifteenth, this is the episode about how to choose.

About the guest: Dr. Gabriel Alizaidy (MD; MS in Precision Health, University of Chicago) came up through CAR-T cancer research at UChicago, runs clinical R&D for a performance-medicine telehealth company, and sat on the FDA's Pharmacy Compounding Advisory Committee that voted this summer to move BPC-157, TB-500, KPV, and MOTS-c toward compounding pharmacies.

5 Key Takeaways

• The one-line diagnosis an FDA panel doctor gives for how most people use peptides.
• Why SS-31 is physical therapy and MOTS-c is exercise for your mitochondria.
• The number of compounds Drew is actually running right now, even though he has vials of everything.
• Why phase three trials for BPC-157 and TB-500 aren't coming, and what a clinical researcher says should stand in for them.
• The reason Gabe says even a knowledgeable person shouldn't build their own stack, and the kind of advisor he thinks belongs in your corner.

Chapters

0:00 Welcome, and how to work with DDT Method
1:24 The #1 peptide mistake: collecting like Pokémon
3:13 Who Gabe is: CAR-T research, telehealth R&D, and the FDA peptide panel
8:17 The new fat-loss compounds, and why he won't rush them
12:53 Mitochondria explained: miles per gallon and exhaust
16:59 The non-negotiables before you inject anything
20:24 SS-31 is physical therapy, MOTS-c is exercise: which comes first
22:58 A word from Amplify Wellness and Janus Optimize
25:33 Low and slow: the doses he won't touch
28:30 Folate, AMPK, and cardiolipin: what the two peptides actually do
33:04 Red light therapy and nitric oxide
38:08 Oxytocin: the peptide for public speaking and connection
42:52 Myostatin inhibitors and FLGR: watching, not touching
47:55 A word from Amplify Wellness, Janus Optimize, and the Skool group
50:09 How Drew finds new compounds, and why RCTs aren't coming
55:56 Less is more: Drew's medicine cabinet confession
1:00:32 Decision fatigue: put the call in an expert's hands
1:06:42 Where to find Gabe

Connect with Dr. Gabriel Alizaidy

Instagram – @gabrielalizaidy

LinkedIn – https://www.linkedin.com/in/galizaidy/

YouTube – https://www.youtube.com/channel/UCiOE4LyFDVoSuQLSLX7SM8A